key: cord-0767495-eigxx5zo authors: Cabo, Julien; Brochier, Alice; Saussoy, Pascale; Dievoet, Marie-Astrid van; Capirchio, Lena; Delire, Bénédicte; Deneys, Véronique title: Positive Direct Antiglobulin Test in COVID-19 patients: decision-making process date: 2021-06-07 journal: Transfus Clin Biol DOI: 10.1016/j.tracli.2021.05.010 sha: 46d7ecf9ec0a01c01408bacb08acd8b42a72bbc0 doc_id: 767495 cord_uid: eigxx5zo In this unprecedented crisis of severe acute respiratory syndrome coronavirus 2 and its associated coronavirus disease 2019 (COVID-19), polymerase chain reaction and then serological testing platforms have been massively developed to face the important screening demand. Polymerase chain reaction and serological testing platforms are not the only actors impacted by the crisis, transfusion services are facing important difficulties. A positive direct antiglobulin test is frequently observed for patients encountering COVID-19. Patients with severe symptoms may develop anaemia and become good candidates for blood transfusions. The interpretation of a positive direct antiglobulin test for patients recently transfused and suffering from COVID-19 is complex. The differentiation between COVID-19 induced antibodies and possible associated transfusion alloantibodies is therefore crucial. In this context, the elution technique incorporated in an appropriate decision-making process plays its full role. This intricate topic is presented through a case report followed by literature review and finally decision-making process for COVID-19 patients necessitating red blood cells administration. A 43-year-old man was hospitalised for hepatorenal syndrome. The patient was confirmed positive to SARS-CoV-2 at the admission by PCR testing. In the first weeks, the patient received oxygen supplementation (2L per day) and presented only minor COVID-19-related symptoms: dyspnoea on exertion, lack of appetite and asthenia. During his stay, the patient faced many cirrhosis complications such as spontaneous bacterial peritonitis, urinary tract infection, terlipressin-induced ischemic skin necrosis with associated haemorrhage, oesophagitis, polyneuropathy, hyponatremia, coagulation disorders. The patient presented aregenerative macrocytic anaemia requiring regular blood transfusions (see Figure 1 ). The anaemia's origin was multifactorial: chronic inflammatory syndrome (CRP level fluctuating between 22,4 mg/L and 124,4 mg/L), hypersplenism secondary to portal hypertension, previous alcohol consumption, malnutrition, vitamin B12 and folate deficiency, impaired coagulation, acute renal impairment, liver cirrhosis and bleeding upon testicular wound. There was no argument for a manifest haemolysis and it was therefore not retained as a possible cause of anaemia. The positive DAT was not associated with the presence of warm autoantibodies by the clinicians/laboratory (see Table 2 for the timeline). The blood smears did not show significative number of schistocytes but showed high number of target cells and significant number of knizocytes along with the formation of few rouleaux and a striking poikilocytosis (see Figure 2 ). Knizocytes, rouleaux formation and poikilocytosis have been recently associated with COVID-19 [1] . Target cells are frequently observed in liver diseases. These red blood cell morphological features were not observed anymore after COVID-19 episode (see Figure 2 ). LDH and indirect bilirubin levels were elevated but constantly decreasing and were most likely due to severe hepatic impairment. Reticulocytes were very low (from 2 to 4 *10³/µL with Nl 30 -100 *10³/µL)) but should be assessed carefully considering patient's acute renal impairment. After injection of darbepoetin alfa 100 µg/ 0,5 ml, reticulocyte count increased to 191*10³/µL and then lessened back to normal values. Haptoglobin levels were measured twice with normal to slightly increased values (1,91 g/L and 2,03 g/L with Nl 0,30 -2,00 g/L). However, the haptoglobin measurements should be interpreted with caution because of hepatic impairment and inflammatory status that respectively decrease and upregulate haptoglobin production. Haemoglobinuria and bilirubinuria trends varied from positive to negative but should again be analysed carefully considering the acute renal impairment with acute tubular necrosis. Bone marrow aspirate examination did not reveal erythroid regeneration in response to anaemia and showed important inflammation features. Increase of proerythroblasts in the bone marrow is normally observed in response to anaemia as they are highly sensitive to erythropoietin secreted by the kidney under hypoxic conditions. However, our patient suffered from acute renal impairment leading to diminished EPO secretion. ABO group control and irregular antibody screening (IAS) were performed before any transfusion of red blood cells (RBCs). IAS had already been tested negative 15 times before first evidence of antibody. A few days before patient's first positive IAS, DAT was performed to investigate the origin of chronic anaemia as the cause was still not obvious for clinicians. The DAT was mixed positive with IgG and C3d specificity. At that time either a positive DAT in a context of AIHA or a post-transfusion alloantibody was suspected but there was no significant manifestation of haemolysis. An acid elution process was performed but the detected immunoglobulins showed neither specificity nor panagglutination. Six days later, IAS and DAT were tested again. This was the first positive IAS for this patient and an antibody screen was performed both with plasma and eluate. The indirect antiglobulin test (IAT) was non-specific with the plasma but an anti-Jka alloantibody was discovered in the 6 eluate. The elution process allowed the hospital blood transfusion service to consider the presence of a transfusion alloantibody and therefore to select Jka negative cross-matched RBCs for patient's safety. The IAT with the plasma revealed four days later the anti-Jka alloantibody but also the appearance of an anti-K alloantibody (see Table 2 ). This case report triggers the importance of performing an elution process for polytransfused patients when an IgG-type DAT is evidenced. The appearance of an alloantibody in the plasma may be delayed if all antibodies are fixed upon their respective antigen at the surface of the RBC membrane. The elution process is a high-burden working process and an appropriate decision-making algorithm is therefore important to limit the situations where it is effectively applicable. It is even more important in this current context in which the patients infected by SARS-COV-2 often present a positive DAT and are prone to multiple transfusions. About seventy-five years ago, the Direct Antiglobulin Test (DAT) was described by R. Coombs who had the innovative idea to use a second antibody, a rabbit AHG, to amplify the agglutination between RBCs sensitized by antibodies [2] . This laboratory testing is now widely used and offers valuable information in many differential diagnosis. The DAT has been slightly redesigned over time. It is still performed by traditional tube agglutination which is the reference method but new more sensitive testing methods now exist such as gel microcolumn method [3] [4] [5] , solid-phase method or more recently flow cytometry [6] [7] [8] . Nowadays, the DAT consists of testing patient's RBCs to investigate the presence of immunoglobulins or complement proteins at the membrane's surface. The test is performed firstly using polyspecific reagents (recognizing both immunoglobulin and complement 7 fragments) and subsequently with monospecific reagents if the polyspecific reagent shows RBCs agglutination [9, 10] . Main situations resulting in positive DAT are Autoimmune Haemolytic Anaemia (AIHA), Immunoallergic Haemolytic Anaemia (IAHA), Alloimmunemediated Haemolytic Transfusion Reaction, and Haemolytic disease of the foetus/newborn [9] [10] [11] . Recently, correlation between COVID-19 and positive DAT has been established. Sensitisation of RBCs by immunoglobulins or complement proteins has been reported several times in different infectious contexts, such as viral and bacterial infections. Infection by Mycoplasma pneumoniae has been frequently associated with autoimmune haemolytic anaemia induced by cold agglutinins that fix complement with anti-I and anti-i specificity [12] [13] [14] [15] . This phenomenon, also called Cold Agglutinin Syndrome (CAS), is a secondary AIHA [16] . Infectious mononucleosis by Epstein-Barr virus has also been frequently associated with CAS [17] [18] [19] [20] [21] . Similarly, several authors have reported the presence of positive DAT consequently to other infectious agents such as Cytomegalovirus [22] [23] [24] [25] , Plasmodium [26] [27] [28] , B19 parvovirus [29] , human immunodeficiency virus-1 [30] [31] [32] , Brucella [33] [34] [35] [36] , adenovirus [37] , Influenza A [38, 39] , Varicella virus [40] [41] [42] , Rubella virus [43] [44] [45] [46] , Legionella pneumophila [47, 48] and Chlamydia pneumoniae [49, 50] . Algassim et al. found significantly lower haemoglobin levels in SARS-CoV-2 infected patients admitted in ICU compared to those in CHW. Drop in haemoglobin levels is associated with poorer prognosis. One hundred sixty-three patients out of 250 (65%) were anaemic in ICU against 111 out of 257 (43%) in CHW [69] . Lower haemoglobin levels for severe COVID-19 have been highlighted in many other studies [70] [71] [72] [73] . A meta-analysis about anaemia in COVID-19 collected data from 40450 patients. The mean haemoglobin level was 12,97 g/dL but significantly lower levels were observed in severe COVID-19 cases [74] . The Kidd (Jk) blood group may generate difficult situations as illustrated by our case report [79] . The elution process is appropriate in the sense that it eluates the potential alloantibodies coated on RBCs while COVID-19 associated antibodies don't give any RBC antigen specificity on commercial panels after elution [61, 62] . COVID-19 autoantibodies are probably attached with low affinity at the RBC membrane and they may be removed during washing step of the elution process. Berzuini et al. also observed that eluates from COVID-19 patients did not react against commercial panel RBCs while they reacted against RBCs prepared from DAT-negative COVID-19 patients. The hyperinflammation state during the disease probably modifies the RBC membrane with exposure of cryptic antigens allowing the binding of complement proteins or immunoglobulins [62] . A decision-making process should be elaborated in hospital blood transfusion services for COVID-19 patients presenting a positive DAT and needing blood transfusion. The algorithm should include DAT-positive COVID-19 patients that will need immediately or in the near future administration of red blood cells because of post-transfusion haemolysis risks. The transfusion timeline may be adequate as a first step in the algorithm. Post-transfusion alloantibodies usually appear 2 to 3 days after the transfusion and elution process is thus not necessary if RBCs have been transfused for less than 3 days. The potential alloantibodies are first entirely fixed on RBCs. They are not circulant yet in the plasma/serum and elution process may therefore be justified. We assume that any transfusion alloantibody will appear in the plasma or serum of the patient after 30 days which renders the elution process worthless after that timeframe. Serum investigation must always be conducted in parallel. IAT should be performed after a positive IAS. In addition to the timeline, the high-burden load of elution process should be taken There are similarities between the plasma of AIHA patients and SARS-CoV 2 patients. Both can present a positive DAT and may be polytransfused. Furthermore, it has been proven that patients with AIHA are at risk of developing transfusion alloantibody even when antigen-matched units are selected [80] . Autoantibodies and alloantibodies coexist in about 1/3 of patients with AIHA [81] . Including the AIHA on this decision-making process would be a potential improvement. However, AIHA management is not exactly similar. The autoantibodies present in AIHA have often panagglutinin specificity after elution process while COVID-19 autoantibodies are removed and don't give any agglutination when eluate is tested. Auto-adsorption is often required to get rid of the autoantibodies in AIHA in order to determine the presence and the specificity of potential alloantibodies [82, 83] . Tailored decision-making process can be implemented in hospital blood transfusion services to help with the management of polytransfused COVID-19 patients presenting a positive DAT. Adequate management process should be in place to avoid severe haemolytic transfusion reactions. This paper aims to help blood transfusion services in their investigations and therefore to improve the quality of patients treatment. Tables Table 1 Haemolysis parameters Table 2 Testing performed by the hospital blood transfusion service Tables Table 1 Haemolysis Legend: ↑= transfusion of RBCs Red blood cell morphology in patients with COVID-19-related anaemia A new test for the detection of weak and incomplete Rh agglutinins Comparison of conventional tube test technique and gel microcolumn assay for direct antiglobulin test: a large study A comparison of conventional tube test and gel technique in evaluation of direct antiglobulin test Comparison of DATs using traditional tube agglutination to gel column and affinity column procedures A preliminary comparison of flow cytometry and tube agglutination assays in detecting red blood cell-associated C3d Simultaneous detection of IgG, IgM, IgA complexes and C3d attached to erythrocytes by flow cytometry Application of flow cytometry in detection of redcell-bound IgG in Coombs-negative AIHA The Direct Antiglobulin Test: Indications, Interpretation, and Pitfalls The direct antiglobulin test: a critical step in the evaluation of hemolysis StatPearls Publishing Copyright © 2020 Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of Mycoplasma pneumoniae Infection Cold Agglutinins in Mycoplasma Infection Mycoplasma pneumoniae associated with severe autoimmune hemolytic anemia: case report and literature review Cold agglutinin-mediated autoimmune hemolytic anemia Acute hemolytic anemia secondary to infectious mononucleosis Acute hemolytic anemia complicating infectious mononucleosis EBV-related Cold Agglutinin Disease Presenting With Conjugated Hyperbilirubinemia: A Pediatric Case Report and Mini Review Fatal autoimmune hemolytic anemia due to immunoglobulin g autoantibody exacerbated by epstein-barr virus INFECTIOUS MONONUCLEOSIS: AN UNSUSPECTED SOURCE ON ANTI-I Hemolytic anemia with positive direct antiglobulin test secondary to spontaneous cytomegalovirus infection in healthy adults Infantile Cytomegalovirus-Associated Severe Warm Autoimmune Hemolytic Anemia: A Case Report Anti-"i" antibody and hemolytic anemia associated with spontaneous cytomegalovirus mononucleosis Infantile cytomegalovirus-associated autoimmune hemolytic anemia Direct Coombs antiglobulin reactions in Gambian children with Plasmodium falciparum malaria. II. Specificity of erythrocyte-bound IgG The direct antiglobulin test in P. falciparum malaria Warm autoimmune hemolytic anemia secondary to Plasmodium ovale infection: a case report and review of the literature Autoimmune hemolytic anemia in patients infected with human immunodeficiency virus-1 HIV-associated autoimmune hemolytic anemia: report of a case and review of the literature HIV-associated autoimmune hemolytic anemia: an update An unusual case of acute brucellosis presenting with Coombs-positive autoimmune hemolytic anemia Acute Brucellosis Presenting as an Autoimmune Hemolytic Anemia Two cases of autoimmune hemolytic anemia secondary to brucellosis: a review of hemolytic disorders in patients with brucellosis Brucellosis-induced autoimmune haemolytic anaemia (AIHA) Cold agglutinin disease associated with adenovirus infection after allogeneic bone marrow transplantation A case of autoimmune hemolytic anemia caused by type A influenza infection in a patient with alcoholic liver cirrhosis Cold agglutinin syndrome associated with a 2009 influenza A H1N1 infection Autoimmune Hemolytic Anemia due to Varicella Infection Autoimmune hemolytic anemia with anti-DC specificity following a primary infection by Varicella virus Cold agglutinin disease after chickenpox Autoimmune hemolytic anemia caused by IgG lambda-monotypic cold agglutinins of anti-Pr specificity after rubella infection Rubella infection with autoimmune hemolytic anemia Autoimmune hemolytic anemia caused by cold agglutinins of the anti-Pr specificity after rubella infection Legionella-Induced Autoimmune Hemolytic Anemia: A Delayed and Unexpected Complication Autoimmune hemolytic anemia and Legionella pneumophila pneumonia Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia COVID-19 infection associated with autoimmune hemolytic anemia Haemolytic anaemia: a consequence of COVID-19 Cold agglutinin disease and autoimmune hemolytic anemia with pulmonary embolism as a presentation of COVID-19 infection Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation SARS-CoV-2 infection in two pediatric patients with immune cytopenias: A single institution experience during the pandemic SARS-CoV-2-associated cold agglutinin disease: a report of two cases Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19) Autoimmune Hemolytic Anemia in a Pediatric Patient With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Autoimmune haemolytic anaemia associated with COVID-19 infection Positive direct antiglobulin tests in patients with COVID-19 Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19 Autoimmune hemolytic anemia in COVID-19 patients, the « transmissible » direct Coombs test Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? Molecular mimicry may explain multi-organ damage in COVID-19 COVID-19 and the Coombs test New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection Predictors of COVID-19 severity: a systematic review and meta-analysis Dynamic changes in routine blood parameters of a severe COVID-19 case Hematologic parameters in patients with COVID-19 infection Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis Transfusion support in COVID-19 patients: Impact on hospital blood component supply during the outbreak. Transfusion Blood use and transfusion needs at a large health care system in Washington state during the SARS-CoV-2 pandemic Blood transfusion during the COVID-19 outbreak Blood transfusion utilization in hospitalized COVID-19 patients The Kidd (JK) Blood Group System Red-blood-cell alloimmunization and prophylactic antigen matching for transfusion in patients with warm autoantibodies Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting Adsorption Technique in Pre-Transfusion Testing For Patients with Warm Type Autoimmune Hemolytic Anemia Elucidation of alloantibodies in autoimmune haemolytic anaemia We thank the blood transfusion hospital staff from our institution for their assistance with decision-making process elaboration and daily application. JC was the first author and the designer of decision-making processes. AB, PS, MvD and VD contributed to the design of the decision-making process and reviewed the manuscript structure and contents. LC and BD contributed to the review of the clinical aspects of the paper. We have no conflict of interest.